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Abstract
The Marshall Smith Syndrome (MSS) is a rare congenital disorder, displaying a constellation of unique symptoms,
including orofacial dysmorphisms, accelerated osseous maturation and dysplasias, mental retardation, and respira-
tory maladies. Few individuals with MSS survive past early childhood. In this case report, we describe a unique
treatment for a 30 year-old patient with MSS who presented to our pain medicine clinic for management of pain
secondary to uncontrolled bilateral hip dysplasias.
Background
The Marshall-Smith Syndrome was first described in 1971
by Marshall et al as a rare congenital disorder, and to date
there are fewer than 40 reported cases [1-3]. The etiology
is unknown but is presumed to be due to a de novo domi-
nant mutation. It is characterized by a constellation of fea-
tures involving the neurologic and respiratory systems,
and accelerated skeletal maturation leading to skeletal dys-
plasias. Patients have retarded intellectual development,
small chins, glossoptosis, prominent eyes, protruding fore-
heads and are small in stature. They generally do not sur-
vive past early childhood mainly due to respiratory
complications, such as aspiration pneumonia. However, if
the respiratory conditions are managed aggressively,
patients have been known to survive longer. To our
knowledge, our patient is one of the oldest living patients
with this rare disorder [3]. Given the natural history of the
syndrome, one would anticipate that older subjects would
suffer a great deal of pain as a result of the accelerated ske-
letal maturation. We report a unique treatment of incapa-
citating bilateral hip pain in a 30 year-old MSS patient
with intra-articular hyaluronate (Hyalgan©).
Case Report
L.W. is a 30 year-old woman with MSS. Her medical his-
tory was obtained from her parents, who accompanied
her and upon whom she was totally dependent for care.
The patient had speech and cognitive impairment that
limited the ability to obtain a direct history. The parents
described a history of worsening hip pain from progres-
sive, bilateral hip dysplasias. Whereas previously their
daughter could ambulate with assistance, she was now
incapacitated by relentless pain. As best as they were able
to determine, the pain radiated from her hips laterally,
down her thighs and provoked regular paroxysms of
screaming, crying and guarding.
Prior to our encounter, this pain had been managed
by an orthopedic surgeon at an outside facility, who
performed a series of nine ultrasound-guided intra-
articular hip steroid injections, over a period of several
years. The last one was performed a few months before
presenting. None of the patient’s previous records were
available to us, but the parents relayed that their daugh-
ter’s response to the injections had begun to wane with
each repeat injection. The most recent recommendation
from the orthopedist was to perform bilateral hip
arthroplasties. The parents were hesitant to pursue this
option, in light of their daughter’s previous surgical
experience, wherein she required an emergency tra-
cheostomy after failed attempts at securing her airway
under anesthesia. Because they were told that future
surgeries would require an “awake” tracheostomy for
airway protection during surgery, they decided to seek
alternative, non-surgical treatments for their daughter’s
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The rest of the review of systems was unremarkable.
Notably, the parents denied any history of bleeding dia-
thesis. Though previous diagnostic imaging was not
available at the time of our initial consultation, they
were reviewed at a later date, prior to treatment, and
revealed dysplasia of both acetabula, and severe osteoar-
thritis and subluxation of both hip joints.
On physical examination, the patient was small in sta-
ture (4ft 2in, 65lbs) and had obvious craniofacial
abnormalities. The neuromuscular exam was limited
due to lack of patient cooperation. The greater trochan-
ters were asymmetrical, with the right side about 2 cm
superior compared to the left. Both were easily palpable
and visibly appeared to be grossly out of socket. Though
muscle tone was good with no flaccidity, the patient’s
inability to obey commands prevented us from assessing
motor or sensory function. Reflex testing revealed patel-
lar and Achilles hyporeflexia.
Based on the patient’s history, physical examination,
and radiographic findings, our impression was that the
patient’s symptoms arose directly from the articular sur-
faces of her hips, and possibly from the bilateral impin-
gement of her lateral femoral cutaneous nerves, as a
result of her inadequately developed acetabula and sub-
luxed femurs. We suggested a series of three fluorosco-
pically guided intra-articular hip injections with sodium
hyaluronate (Hyalgan©), administered weekly. In the
event of an unsatisfactory result from the injections, we
intended to perform bilateral lateral femoral cutaneous
nerve blocks. The patient’s parents elected to pursue
injection of sodium hyaluronate, and scheduled an
appointment for the procedure.
Method
After discussing the risks, benefits, and alternatives on
the day of the procedure, informed consent was obtained
from the patient’s parents. Her parents were present dur-
ing the entire procedure, to facilitate cooperation. After
placement on the fluoroscopy table in the supine posi-
tion, the region of the greater trochanters were cleansed
with chlorhexidine (Cholraprep©) and draped fully. The
fluoroscopic camera was positioned to visualize the right
greater trochanter, femoral neck and acetabulum in the
AP projection (Figure 1). Using a sterile marker, we
marked the needle insertion site one centimeter cephalad
to the greater trochanter. A 25-gauge, 1-1/2 inch needle
was used to infiltrate the skin with 1% lidocaine. Subse-
quently, a 3-1/2 inch, 22-gauge spinal needle was
advanced to the femoral neck and into the joint capsule
at this level. Following this, after negative aspiration for
blood, 1 milliliter (ml) of iopamidol-300 (Isovue-300©)
dye was injected, verifying intra-articular spread of the
dye (Figure 2). This was followed with an injection of 2
mL of 0.5% preservative-free bupivacaine and 2 ml
(20 mg) of Hyalgan© into the joint space. The same pro-
cedure was repeated on the left hip. The patient tolerated
the procedure well without complications. We discharged
the patient home after meeting discharge criteria. The
patient returned to our clinic for a total of three injec-
tions of Hyalgan©, separated by one week.
Discussion
Marshall et al. first described this rare congenital dis-
order in 1971 as a sporadic entity of unknown etiology
Figure 1 A fluoroscopic image of the patient’s right hip, taken
prior to needle insertion for intra-articular hip injection.
Figure 2 A right hip fluoroscopic image with needle in place,
showing spread of contrast within joint capsule. Contrast spread
is apparent from the base of the femoral neck and around joint.
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[4,5]. Patients classically have a normal karyotype and
are born of nonconsanguineous parents [4]. Most signif-
icantly, they display skeletal maturation that is advanced
for age, along with osteopenia and sclerosis, leading
some to describe this kind of ossification as “disharmo-
nic” [6-8]. Skeletal abnormalities like broadened pha-
langes with abnormal epiphyses, thinned or bowing long
bones, and dysmorphic vertebrae leading to scoliosis,
kyphosis, or cervical, thoracic, or lumbar instability are
commonly present [[3-5,7-9], Figure 3, Figure 4, Figure
5, Figure 6]. Specific facial anomalies may include
hypertrichosis, prominent eyes and forehead (frontal
bossing), megalocornea, blue sclerae, a flat nasal bridge,
micrognathia, and anteverted nostrils [5,10]. Neurologic
derangements may consist of an absent corpus callosum,
macrogyria, ventricular dilatation or hydrocephalus,
periventricular leukomalacia, resulting in motor and
mental retardation [5,10]. They might also display optic
nerve hypoplasia [11]. It should be noted that not all
patients afflicted with MSS display the same anatomic
findings.
Most infants affected with MSS succumb to death
early in life. This is usually due to pulmonary complica-
tions, such as aspiration and chronic lung obstruction
leading to pulmonary infections, pulmonary hyperten-
sion, and right heart failure [2,4,5,10-13].
The concept of applying viscosupplementation (VS),
using modified hyaluronic acid to form hyaluronans
(HA) and their cross-linked derivatives, to the treat-
ment of osteoarthritis arose in the mid 1970’s, though
these compounds had also been investigated for use in
various ophthalmologic procedures [14-17]. As joints
affected by osteoarthritis are depleted of their natural
synovial fluid, which contains the glycosaminoglycan
hyaluronic acid, it was postulated that injecting exo-
genous HA would increase the viscosity and elasticity
to the joint, thereby improving joint function and
relieving symptoms [18,19]. While research on, and
FDA-approval of, VS is primarily for use in the treat-
ment of knee osteoarthritis, it has also been used suc-
cessfully in small trials for the treatment of arthritis of
the temporomandibular, sacroiliac, hip, shoulder, foot,
and ankle joints [17,20-23]. In 1997, Hyalgan® (sodium
Figure 3 A wrist/hand X-ray of a female with MSS, at
chronological age of 18 weeks displaying wide phalanges &
stippled epiphyses, showing bone age of 1.9 years [9].
Figure 4 An X-ray showing thinned ribs and dysmorphic
lumbar vertebrae in a 4-week old male with MSS [4].
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hyaluronate), a high molecular-weight HA obtained
from rooster ’s combs, was approved by the FDA
[24,25]. Like other HA, it is only approved for osteoar-
thritis of the knee, and should be used with caution in
patients with sensitivities to avian proteins, feathers,
and egg products. It also carries a similar side-effect
profile, including local inflammation, injection site
pain and itching, anaphylaxis/anaphylactoid reactions,
local ecchymosis, nausea/vomiting, diarrhea, anorexia,
and headache [26]. While Hyalgan© has a relatively
short half-life of about twenty-four hours, the effect of
the injections lasts for weeks, which suggests that it
augments natural synovium production, mitigates
nociception and inflammation, as well as increases the
rheological properties (viscosity, elasticity, pseudoplas-
ticity) of synovial fluid [27-29].
Our patient ’s survival to adulthood is somewhat
anomalous, compared to the life expectancy of others
afflicted with MSS. Therefore, we can only assume that
if other carriers of the disease survived the historically
perilous respiratory maladies of childhood, they too
would suffer from the chronic pain of disharmonic ske-
letal development and ensuing arthralgias, as we
observed in our patient, and as it has been noted in
other carriers [13]. L.W. underwent a series of three
intra-articular bilateral hip injections one week apart,
and gradual improvement in symptoms over this period
was noted. At the time of the first visit, the patient
arrived in her wheelchair, and passive movement of her
hips caused her great distress. Two months after the last
injection, we reevaluated the patient in our clinic. She
arrived for her appointment walking, semi-indepen-
dently, with her parents on either side of her. They felt
that the injections successfully decreased the frequency
and intensity of her painful episodes, noting a marked
improvement in her daily functioning.
Conclusion
We describe a unique treatment alternative for a patient
with Marshall Smith Syndrome and debilitating, painful
bilateral hip dysplasias using intra-articular sodium hya-
luronate injections. This management option should be
Figure 5 Femur and Tibia X-ray of 7 year-old female with MSS
demonstrating dysplastic hips with shallow, horizontal
acetabula, post-traumatic bowing, Arrow indicates healing
tibial fracture. Diaphyses are gracile with thin cortices and
obliterated medullae, in contrast with widened metaphyses and
epiphyses, which are relatively spared [13].
Figure 6 X-ray of lumbar spine demonstrating an apex left
45 degree scoliosis in the same 7 year-old female with MSS [13].
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considered in one’s armamentarium, especially in the
high-risk surgical population.
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